NASDAQ · SRRK
Scholar Rock Holding Corporation
$44.18+$0.93 (+2.15%)
Scholar Rock Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
Loading market information…
NYSE · PRGO · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Perrigo Company plc’s quoted price sits in the upper half of its reported 52-week range, 25.46% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Perrigo Company plc’s forward annual dividend is $1.16 per share, paid quarterly. The forward yield is 7.3% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Perrigo Company plc’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $0.51. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Perrigo Company plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 7, 2025 | $0.60+7.14% vs estimate | $1.04B-3.01% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $0.93+1.09% vs estimate | $1.14B+4.45% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | $0.81-1.22% vs estimate | $1.09B-9.22% vs estimate |
|---|
THE ANALYST VIEW
36 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$44.18+$0.93 (+2.15%)
Scholar Rock Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
$60.53+$1.43 (+2.42%)
Heartflow, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$14.49$0.00 (0.0%)
Amicus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.07% below the high.
$81.25+$0.59 (+0.73%)
LivaNova PLC’s quoted price sits in the upper half of its reported 52-week range, 5.26% below the high.
$74.20+$2.15 (+2.98%)
Tarsus Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.93% below the high.
$8.91+$1.99 (+28.76%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.44% below the high.
$23.21-$0.03 (-0.13%)
Surgery Partners, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.68% below the high.
$13.59+$0.27 (+2.03%)
HUTCHMED (China) Limited’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
